PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2014 | 10 | 1 |
Article title

Assessment of the feasibility of TACE combined with intratumoral injection of cisplatin in hepatocellular carcinoma

Content
Title variants
Languages of publication
EN
Abstracts
EN
The feasibility of transcatheter arterial chemoembolization (TACE) combined with intratumoral injection of cisplatin as treatment for hepatocellular carcinoma. 30 cases receiving TACE were denoted the TACE group, another 30 cases receiving TACE combined with an intratumoral multi-point injection of cisplatin were denoted the TACE/cisplatin group. Cases with partial remission/complete remission (PR/CR) were analyzed using 2 tests; alpha fetoprotein (AFP), aspartate amino transferase (AST), total bilirubin (TBIL), erythrocyte, and platelet levels were detected and the differences between two groups were analyzed using the Student’s t-test; cases with complications, including intrahepatic metastasis (IM), upper gastrointestinal bleeding (UGB), and liver failure were also counted. The correlation of clinical parameters with PR/CR was analyzed using multifactorial correlation analysis. Cases with PR/CR in the TACE/cisplatin group were significantly more than in TACE group, accompanied by significant declination in FAP. There were no significant differences of AST, ALT, TBIL, blood urea nitrogen (BUN), white blood cells (WBC), red blood cells (RBC), and platelets (PLT) between two groups; 3 cases with IM, one case with UGB and one case with LF were found in the TACE group, but only 1 case with IM was found in the TACE/cisplatin group. In addition, tumor stage was correlated with PR/CR. We concluded that TACE combined with intratumoral injection of cisplatin was more effective than TACE, and with fewer complications and side effects.
Publisher
Journal
Year
Volume
10
Issue
1
Physical description
Dates
published
1 - 1 - 2015
received
10 - 7 - 2015
online
17 - 12 - 2015
accepted
30 - 9 - 2015
References
  • [1] Wang Z., Chapiro J., Schernthaner R., et al., Multimodality 3D Tumor Segmentation in HCC Patients Treated with TACE, Academic radiology, 2015
  • [2] Xie Z.B., Wang X.B., Chen J., et al., Letter: Is DEB-TACE associated with better tumor response than cTACE in meta-analysis? authors’ reply, Hepatology research, the official journal of the Japan Society of Hepatology, 2015
  • [3] El-Halawany M.S., Ismail H.M., Zeeneldin A.A., et al., Investigating the pretreatment miRNA expression patterns of advanced hepatocellular carcinoma patients in association with response to TACE treatment, BioMed research international, 2015, 649-750
  • [4] Fu-Hua, Yan K.R.Z., Jie-Min C., et al., Role and limitation of FMPSPGR dynamic contrast scanning in the follow-up of patients with hepatocellular carcinoma treated by TACE, World J. Gastroenterol, 2002, 8(4), 658-662
  • [5] Wu P.F., Lin C.H, Kuo C.H., et al., A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis, BMC Cancer, 2015, 15(1), 1290-1291[Crossref][WoS]
  • [6] Cross M.J., Dixelius J., Matsumoto T., Claesson-Welsh L., VEGF-receptor signal transduction, Trends in Biochemical Sciences, 2003, 28(9), 488-494
  • [7] Prudovsky I.M.A., Soldi R., et al., The non-classical export routes: FGF1 and IL-1alpha point the way, J. Cell Sci., 2003, 116(24), 4871-4881
  • [8] Cuevas-Antonio R.C., Arechavaleta-Velasco C.F., et al., Expression of Progranulin (Acrogranin/PCDGF/Granulin- Epithelin Precursor) in Benign and Malignant Ovarian Tumors and Activation of MAPK Signaling in Ovarian Cancer Cell Line, Cancer Investigation, 2010, 28(5), 452-458
  • [9] Abu-Zeinah G., Owen D., Prieto-Granada C., et al., From the liver to the foot: a case of systemic embolism and acrometastasis in hepatocellular carcinoma, Gastrointestinal cancer research, G.C.R., 2014, 7(3-4), 103-107
  • [10] Taupin D., Mukherjee V., Nathavitharana R., et al., Lipiodol embolism following transarterial chemoembolization: an atypical case, Critical care medicine, 2014, 42(6), 481-484
  • [11] Ahmad A., Chen S.L., Bilchik A.J., Role of repeated hepatectomy in the multimodal treatment of hepatic colorectal metastases, Archives of surgery (Chicago, Ill : 1960), 2007, 142(6), 526-531
  • [12] Shankar S., VanSonnenberg E., Morrison P.R., et al., Combined radiofrequency and alcohol injection for percutaneous hepatic tumor ablation, AJR American journal of roentgenology, 2004, 183(5), 1425-1429
  • [13] Wang Y., Liu Y., Liu Y., et al., A polymeric prodrug of cisplatin based on pullulan for the targeted therapy against hepato cellular carcinoma, International journal of pharmaceutics, 2015, 483(1-2), 89-100
  • [14] Li J., Lei B., Nie X., et al., A comprehensive method for predicting fatal liver failure of patients with liver cancer resection, Medicine, 2015, 94(17), 784[Crossref][WoS]
  • [15] Fujisaki S., Takashina M., Tomita R., et al., Treatment of repeat TACE plus S-1 for multiple intrahepatic recurrence of hepatoma and gastric cancer, Gan to kagaku ryoho Cancer & chemotherapy, 2014, 41(12), 2151-2153
  • [16] Kirihara M., Nagashima M., Higuchi K., et al., A case report of unresectable hepatocellular carcinoma (HCC) with portal vein tumor thrombus responding to DSM-TACE (degradable starch microspheres-transcatheter arterial chemoembolization), Gan to kagaku ryoho Cancer & chemotherapy, 2010, 37(12), 2705-2707
  • [17] Li C.Y., Wang X.L., Wang J.H., et al., Identifying serum biomarkers for TACE therapy efficiency of hepatocellular carcinoma, Frontiers in bioscience (Elite edition), 2011, 3, 212-220
Document Type
Publication order reference
YADDA identifier
bwmeta1.element.-psjd-doi-10_1515_med-2015-0075
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.